Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114

Affiliations

¹ CNR Institute of Clinical Physiology, Pisa, Italy ferranni@ifc.cnr.it.
² Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Comment

Ele Ferrannini et al. Diabetes Care. 2016 Dec.

. 2016 Dec;39(12):e226.

doi: 10.2337/dci16-0033.

¹ CNR Institute of Clinical Physiology, Pisa, Italy ferranni@ifc.cnr.it.
² Cardiometabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

No abstract available

Comment on

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ferrannini E, Mark M, Mayoux E. Ferrannini E, et al. Diabetes Care. 2016 Jul;39(7):1108-14. doi: 10.2337/dc16-0330. Diabetes Care. 2016. PMID: 27289126
Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114.
Jordan J, El-Armouche A, Hanefeld M, Bornstein SR, Birkenfeld AL. Jordan J, et al. Diabetes Care. 2016 Dec;39(12):e224-e225. doi: 10.2337/dc16-1588. Diabetes Care. 2016. PMID: 27879363 No abstract available.